Replies to post #247423 on Biotech Values

[DewDiligence]

And setting aside first-gen agents with unstable linkers, I really don't think different linker technologies are going to make a meaningful difference in [safety and, therefore,] efficacy.

Why would the current generation of linker technology not be improvable?